content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation
and recommendation
Medistem, Inc. (MEDS)
-0.56
(-56.00%)
content_middle
Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
Previous Close:
8.10
Open:
N/A
Bid:
N/A
Ask:
N/A
1yr Target Price:
N/A
Day's Range:
N/A - N/A
52wk Range:
3.89 - 44.56
Volume:
N/A
Average Daily Volume:
N/A
Market Capitalization:
0.00M
Trailing Annual Dividend Yield:
N/A
Shares Outstanding:
0.00M
content_right
- March 7, 2014 - 4:22pm | Research Notes
- December 26, 2013 - 9:36am | Research Notes
- December 20, 2013 - 8:57am | Research Notes
- November 16, 2013 - 6:39pm | Research Notes
- November 14, 2013 - 9:51am | Out and About
- September 16, 2013 - 5:49pm | Research Notes
- August 15, 2013 - 10:12am | IP & Patents
- July 29, 2013 - 12:44pm | Research Notes, Regulatory
- July 18, 2013 - 10:04am | Research Notes, IP & Patents
- July 16, 2013 - 7:02pm | Research Notes, Financings
- July 10, 2013 - 7:46pm | BOD & C-Suite Updates
- June 26, 2013 - 9:43pm | Out and About
- May 21, 2013 - 8:07pm | Out and About, BOD & C-Suite Updates
- June 29, 2012 - 11:39am | IP & Patents
- June 24, 2010 - 8:49am